Pub Date : 2023-06-01DOI: 10.21608/aps.2023.204521.1116
Sarah Fahmy, Mona Alshahawy, Nourhan S. Mohamed, Nora Gamal, S. Abdelazim, Nadia Abdelsalam, Hend Abdelrahim, Reem Shehab, L. E. El Wakeel
Increasing the prevalence of Parkinson‘s disease is an alarming sign that needs attention, so focusing on new medications and regimens which play an important role in prevention and treatment becomes a point of concern. Parkinson's disease is the second neurodegenerative disorder caused by the interplay between different mechanisms that are related to genetics, environment, and other factors. One of the potential treatment options under research is nicotinamide which may act as a neuroprotective agent. Although nicotinamide is accepted as a therapeutic agent in many diseases, its action as a Nicotinamide adenine dinucleotide (NAD) precursor against oxidative stress needs to be proved in Parkinson‘s disease. Here, based on the current literature, we provide a thorough overview of nicotinamide usage in medicine. We summarize chemistry, uses, side effects, different mechanisms, and all available preclinical and clinical data about the activity of nicotinamide. Nicotinamide increases cytoprotection, the release of dopamine, and decreases oxidative stress of mitochondria. As a consequence, we believe that nicotinamide may become a potential drug in the treatment of Parkinson‘s patients.
{"title":"The use of Nicotinamide in Parkinson’s disease; A Possible path to the future. Review Article","authors":"Sarah Fahmy, Mona Alshahawy, Nourhan S. Mohamed, Nora Gamal, S. Abdelazim, Nadia Abdelsalam, Hend Abdelrahim, Reem Shehab, L. E. El Wakeel","doi":"10.21608/aps.2023.204521.1116","DOIUrl":"https://doi.org/10.21608/aps.2023.204521.1116","url":null,"abstract":"Increasing the prevalence of Parkinson‘s disease is an alarming sign that needs attention, so focusing on new medications and regimens which play an important role in prevention and treatment becomes a point of concern. Parkinson's disease is the second neurodegenerative disorder caused by the interplay between different mechanisms that are related to genetics, environment, and other factors. One of the potential treatment options under research is nicotinamide which may act as a neuroprotective agent. Although nicotinamide is accepted as a therapeutic agent in many diseases, its action as a Nicotinamide adenine dinucleotide (NAD) precursor against oxidative stress needs to be proved in Parkinson‘s disease. Here, based on the current literature, we provide a thorough overview of nicotinamide usage in medicine. We summarize chemistry, uses, side effects, different mechanisms, and all available preclinical and clinical data about the activity of nicotinamide. Nicotinamide increases cytoprotection, the release of dopamine, and decreases oxidative stress of mitochondria. As a consequence, we believe that nicotinamide may become a potential drug in the treatment of Parkinson‘s patients.","PeriodicalId":8314,"journal":{"name":"Archives of Pharmaceutical Sciences Ain Shams University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86253725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.21608/aps.2023.202432.1115
S. Gad, Riham Elgogary, A. Geneidi, R. Hathout
The blood-brain barrier (BBB) is an essential component in safeguarding the brain and preserving its equilibrium. The BBB represents a challenge for various types of drug delivery systems, particularly in the context of treating numerous neuropathological disorders wherein the therapeutic agents cannot cross the BBB. Nonetheless, existing neurotherapeutics have drawbacks such as toxicity and lack of specificity. Advances in nano drug delivery systems, particularly lipid-based nanocarriers, aim to deliver active therapeutics across the BBB to improve neurological conditions such as Alzheimer's, Parkinson's, and brain tumors, offering a novel treatment strategy with enhanced drug delivery, increased target specificity, enhanced efficacy, and more significantly, minimized toxicity in a biomimetic manner. In this context, this review sheds light on the use of lipid nanocarriers loaded with drugs of natural origin such as ferulic acid, resveratrol, curcumin, and rosmarinic acid for their brain delivery with better bioavailability and exceptional improvement in their therapeutic potential to treat major neurological disorders in future clinics.
{"title":"Lipid nanocarriers encapsulating herbal drugs for brain diseases therapy","authors":"S. Gad, Riham Elgogary, A. Geneidi, R. Hathout","doi":"10.21608/aps.2023.202432.1115","DOIUrl":"https://doi.org/10.21608/aps.2023.202432.1115","url":null,"abstract":"The blood-brain barrier (BBB) is an essential component in safeguarding the brain and preserving its equilibrium. The BBB represents a challenge for various types of drug delivery systems, particularly in the context of treating numerous neuropathological disorders wherein the therapeutic agents cannot cross the BBB. Nonetheless, existing neurotherapeutics have drawbacks such as toxicity and lack of specificity. Advances in nano drug delivery systems, particularly lipid-based nanocarriers, aim to deliver active therapeutics across the BBB to improve neurological conditions such as Alzheimer's, Parkinson's, and brain tumors, offering a novel treatment strategy with enhanced drug delivery, increased target specificity, enhanced efficacy, and more significantly, minimized toxicity in a biomimetic manner. In this context, this review sheds light on the use of lipid nanocarriers loaded with drugs of natural origin such as ferulic acid, resveratrol, curcumin, and rosmarinic acid for their brain delivery with better bioavailability and exceptional improvement in their therapeutic potential to treat major neurological disorders in future clinics.","PeriodicalId":8314,"journal":{"name":"Archives of Pharmaceutical Sciences Ain Shams University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86276183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.21608/aps.2023.206876.1118
S. Mabrouk, Ghada R Abdellatif, A. Abu zaid, Khaled Aboshanab
Gram-negative bacterial (GNB) infections represent a worldwide serious public health challenge, especially with the increased global spread of carbapenem resistance (CR) among these pathogens. There are different forms of CR including, intrinsic and acquired mechanisms, one of the most significant of which is carbapenemase production. In the last decade, the widespread plasmid-mediated carbapenemase production, on top of the chromosomally encoded carbapenemases-already abundant since the 1990s-further complicated the situation and necessitated urgent intervention to further understand and tackle this issue. In this review, the phenotypic and genotypic methods for the detection of different types of carbapenemase have been discussed. Also, the different control measures and strategies that should be applied in an attempt to control the massive spread of GNB infections especially in healthcare facilities, have been elaborated on in this article. The challenges of GNB-associated infection in terms of the emergence of resistance to carbapenems, the last line of defense against GNB, and the continuing spread of this resistance left us with almost no options for treatment as well as their complication on the host. On the other hand, we explore the various opportunities for their control such as the development of new classes of antimicrobials and the structural modification of existing ones. It is also inevitable to explore novel treatment options including the association of antimicrobial agents with non-antimicrobials, inhibition of quorum sensing, bacteriophage therapy, photodynamic therapy, and monoclonal antibodies for treatment and prevention.
{"title":"New Insights on the Carbapenem-resistant Gram Negative-associated-Infections: Challenges and Opportunities","authors":"S. Mabrouk, Ghada R Abdellatif, A. Abu zaid, Khaled Aboshanab","doi":"10.21608/aps.2023.206876.1118","DOIUrl":"https://doi.org/10.21608/aps.2023.206876.1118","url":null,"abstract":"Gram-negative bacterial (GNB) infections represent a worldwide serious public health challenge, especially with the increased global spread of carbapenem resistance (CR) among these pathogens. There are different forms of CR including, intrinsic and acquired mechanisms, one of the most significant of which is carbapenemase production. In the last decade, the widespread plasmid-mediated carbapenemase production, on top of the chromosomally encoded carbapenemases-already abundant since the 1990s-further complicated the situation and necessitated urgent intervention to further understand and tackle this issue. In this review, the phenotypic and genotypic methods for the detection of different types of carbapenemase have been discussed. Also, the different control measures and strategies that should be applied in an attempt to control the massive spread of GNB infections especially in healthcare facilities, have been elaborated on in this article. The challenges of GNB-associated infection in terms of the emergence of resistance to carbapenems, the last line of defense against GNB, and the continuing spread of this resistance left us with almost no options for treatment as well as their complication on the host. On the other hand, we explore the various opportunities for their control such as the development of new classes of antimicrobials and the structural modification of existing ones. It is also inevitable to explore novel treatment options including the association of antimicrobial agents with non-antimicrobials, inhibition of quorum sensing, bacteriophage therapy, photodynamic therapy, and monoclonal antibodies for treatment and prevention.","PeriodicalId":8314,"journal":{"name":"Archives of Pharmaceutical Sciences Ain Shams University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89302740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.21608/aps.2023.198691.1111
A. Elshamy, S. Saleh, Khaled Aboshanab, M. Aboulwafa, Nadia Hassouna
{"title":"In Vitro Meropenem/Antibiotic and Meropenem/Bacteriophage Combinations Against Carbapenem-Resistant Gram-Negative Uropathogens","authors":"A. Elshamy, S. Saleh, Khaled Aboshanab, M. Aboulwafa, Nadia Hassouna","doi":"10.21608/aps.2023.198691.1111","DOIUrl":"https://doi.org/10.21608/aps.2023.198691.1111","url":null,"abstract":"","PeriodicalId":8314,"journal":{"name":"Archives of Pharmaceutical Sciences Ain Shams University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87064073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.21608/aps.2023.194792.1109
Sara Barakat, M. Nasr, N. Mortada, S. Badawy
{"title":"Preparation and characterization of mangiferin-loaded lipid nanocapsules","authors":"Sara Barakat, M. Nasr, N. Mortada, S. Badawy","doi":"10.21608/aps.2023.194792.1109","DOIUrl":"https://doi.org/10.21608/aps.2023.194792.1109","url":null,"abstract":"","PeriodicalId":8314,"journal":{"name":"Archives of Pharmaceutical Sciences Ain Shams University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84578257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-01DOI: 10.21608/aps.2022.168128.1101
walaa Elsherbeeny, Riham I. El-Gogary, M. Nasr, O. Sammour
The oral route of administration is considered the easiest, most convenient, and most widely used drug delivery route. One of the hardest challenges facing oral drug delivery systems (DDS) is the erratic absorption of drugs through the gastrointestinal tract (GIT). The conventional oral dosage forms usually suffer from low bioavailability, especially in the case of drugs with narrow absorption windows (NAW). The oral controlled-release dosage forms could overcome the previous limitation by providing predicted and calculated drug release, resulting in an improvement of the efficacy of drugs. One of the most promising types of oral controlled-release dosage forms for this purpose is the gastro retentive drug delivery system (GRDDS), which was found to improve the gastric retention of the dosage form and maximize the absorption and bioavailability of the drugs with NAW. In this review, we summarize the different GRDDS techniques used for improving drug absorption, their methods of preparation, and their mechanisms of action.
{"title":"Current progress of oral site-specific dosage forms: Emphasis on gastroretentive drug delivery systems","authors":"walaa Elsherbeeny, Riham I. El-Gogary, M. Nasr, O. Sammour","doi":"10.21608/aps.2022.168128.1101","DOIUrl":"https://doi.org/10.21608/aps.2022.168128.1101","url":null,"abstract":"The oral route of administration is considered the easiest, most convenient, and most widely used drug delivery route. One of the hardest challenges facing oral drug delivery systems (DDS) is the erratic absorption of drugs through the gastrointestinal tract (GIT). The conventional oral dosage forms usually suffer from low bioavailability, especially in the case of drugs with narrow absorption windows (NAW). The oral controlled-release dosage forms could overcome the previous limitation by providing predicted and calculated drug release, resulting in an improvement of the efficacy of drugs. One of the most promising types of oral controlled-release dosage forms for this purpose is the gastro retentive drug delivery system (GRDDS), which was found to improve the gastric retention of the dosage form and maximize the absorption and bioavailability of the drugs with NAW. In this review, we summarize the different GRDDS techniques used for improving drug absorption, their methods of preparation, and their mechanisms of action.","PeriodicalId":8314,"journal":{"name":"Archives of Pharmaceutical Sciences Ain Shams University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86628834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-01DOI: 10.21608/aps.2023.189963.1105
H. Azzam, M. El-Derany, S. Wahdan, R. Faheim, Gouda Kamel, Ebtehal El-Demerdash Zaki
{"title":"Taurine upregulated 1: Prognostic biomarker in breast cancer","authors":"H. Azzam, M. El-Derany, S. Wahdan, R. Faheim, Gouda Kamel, Ebtehal El-Demerdash Zaki","doi":"10.21608/aps.2023.189963.1105","DOIUrl":"https://doi.org/10.21608/aps.2023.189963.1105","url":null,"abstract":"","PeriodicalId":8314,"journal":{"name":"Archives of Pharmaceutical Sciences Ain Shams University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91271709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-01DOI: 10.21608/aps.2022.155127.1098
Shorouk A Alafifi, S. Wahdan, D. Elsherbiny, S. Azab
Chemotherapy is considered to be the most effective intervention in cancer treatment. The first use of chemotherapy began in the 1940s, unfortunately, its use result in many serious and debilitating side effects which affect human daily activities. Doxorubicin is a powerful antineoplastic drug FDA-approved for the management of a variety of cancer types including leukemia and lymphoma. However, its clinical use is limited due to its toxic effect on different tissues including testicular toxicity which has a bad impact on the quality of life of cancer survivors. DOX-induced testicular toxicity is accompanied by defects in sperm analysis including low sperm count, low sperm motility, and high sperm abnormalities in addition to affecting steroidogenesis. This review is intended to discuss the pharmacodynamics and the pharmacokinetics of doxorubicin, besides the possible underlying mechanisms that may be contributed to the damage of testicles caused by DOX including oxidative stress, inflammation, apoptosis, and autophagy. Moreover, the assessment of post-chemotherapy testicular toxicity in animals and the promising pharmacological treatment that has been studied in animal models were discussed.
{"title":"Doxorubicin-induced testicular toxicity: possible underlying mechanisms and promising pharmacological treatments in experimental models.","authors":"Shorouk A Alafifi, S. Wahdan, D. Elsherbiny, S. Azab","doi":"10.21608/aps.2022.155127.1098","DOIUrl":"https://doi.org/10.21608/aps.2022.155127.1098","url":null,"abstract":"Chemotherapy is considered to be the most effective intervention in cancer treatment. The first use of chemotherapy began in the 1940s, unfortunately, its use result in many serious and debilitating side effects which affect human daily activities. Doxorubicin is a powerful antineoplastic drug FDA-approved for the management of a variety of cancer types including leukemia and lymphoma. However, its clinical use is limited due to its toxic effect on different tissues including testicular toxicity which has a bad impact on the quality of life of cancer survivors. DOX-induced testicular toxicity is accompanied by defects in sperm analysis including low sperm count, low sperm motility, and high sperm abnormalities in addition to affecting steroidogenesis. This review is intended to discuss the pharmacodynamics and the pharmacokinetics of doxorubicin, besides the possible underlying mechanisms that may be contributed to the damage of testicles caused by DOX including oxidative stress, inflammation, apoptosis, and autophagy. Moreover, the assessment of post-chemotherapy testicular toxicity in animals and the promising pharmacological treatment that has been studied in animal models were discussed.","PeriodicalId":8314,"journal":{"name":"Archives of Pharmaceutical Sciences Ain Shams University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87384054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-01DOI: 10.21608/aps.2022.153765.1096
Mohamed A. Raslan, Lamia Elwakeel, S. Shahin
{"title":"The effect of OCT-2 inhibitor Daclatasvir on Metformin pharmacokinetics and pharmacodynamics at two dose levels: A Bayesian approach using Markov-Chain Monte Carlo simulations","authors":"Mohamed A. Raslan, Lamia Elwakeel, S. Shahin","doi":"10.21608/aps.2022.153765.1096","DOIUrl":"https://doi.org/10.21608/aps.2022.153765.1096","url":null,"abstract":"","PeriodicalId":8314,"journal":{"name":"Archives of Pharmaceutical Sciences Ain Shams University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83212066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-01DOI: 10.21608/aps.2023.166675.1100
A. Saleh, Nermin Victor, Amira Elkosasy
{"title":"Spectrofluorometric Determination of Baricitinib in Pure Form and Application on Pharmaceutical Dosage Form; Green Profile Evaluation via Eco-scale and GAPI Tools.","authors":"A. Saleh, Nermin Victor, Amira Elkosasy","doi":"10.21608/aps.2023.166675.1100","DOIUrl":"https://doi.org/10.21608/aps.2023.166675.1100","url":null,"abstract":"","PeriodicalId":8314,"journal":{"name":"Archives of Pharmaceutical Sciences Ain Shams University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76179571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：